Isaac See1, Runa H Gokhale1, Andrew Geller1, Maribeth Lovegrove1, Asher Schranz2, Aaron Fleischauer3,4, Natalie McCarthy1, James Baggs1, Anthony Fiore1. 1. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA. 3. North Carolina Department of Health, Raleigh, North Carolina, USA. 4. Career Epidemiology Field Officer, Centers for Disease Control and Prevention, Atlanta, Georgia, UA.
Abstract
BACKGROUND: Despite concerns about the burden of the bacterial and fungal infection syndromes related to injection drug use (IDU), robust estimates of the public health burden of these conditions are lacking. The current article reviews and compares data sources and national burden estimates for infective endocarditis (IE) and skin and soft-tissue infections related to IDU in the United States. METHODS: A literature review was conducted for estimates of skin and soft-tissue infection and endocarditis disease burden with related IDU or substance use disorder terms since 2011. A range of the burden is presented, based on different methods of obtaining national projections from available data sources or published data. RESULTS: Estimates using available data suggest the number of hospital admissions for IE related to IDU ranged from 2900 admissions in 2013 to more than 20 000 in 2017. The only source of data available to estimate the annual number of hospitalizations and emergency department visits for skin and soft-tissue infections related to IDU yielded a crude estimate of 98 000 such visits. Including people who are not hospitalized, a crude calculation suggests that 155 000-540 000 skin infections related to IDU occur annually. DISCUSSION: These estimates carry significant limitations. However, regardless of the source or method, the burden of disease appears substantial, with estimates of thousands of episodes of IE among persons with IDU and at least 100 000 persons who inject drugs (PWID) with skin and soft-tissue infections annually in the United States. Given the importance of these types of infections, more robust and reliable estimates are needed to better quantitate the occurrence and understand the impact of interventions. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Despite concerns about the burden of the bacterial and fungal infection syndromes related to injection drug use (IDU), robust estimates of the public health burden of these conditions are lacking. The current article reviews and compares data sources and national burden estimates for infective endocarditis (IE) and skin and soft-tissue infections related to IDU in the United States. METHODS: A literature review was conducted for estimates of skin and soft-tissue infection and endocarditis disease burden with related IDU or substance use disorder terms since 2011. A range of the burden is presented, based on different methods of obtaining national projections from available data sources or published data. RESULTS: Estimates using available data suggest the number of hospital admissions for IE related to IDU ranged from 2900 admissions in 2013 to more than 20 000 in 2017. The only source of data available to estimate the annual number of hospitalizations and emergency department visits for skin and soft-tissue infections related to IDU yielded a crude estimate of 98 000 such visits. Including people who are not hospitalized, a crude calculation suggests that 155 000-540 000 skin infections related to IDU occur annually. DISCUSSION: These estimates carry significant limitations. However, regardless of the source or method, the burden of disease appears substantial, with estimates of thousands of episodes of IE among persons with IDU and at least 100 000 persons who inject drugs (PWID) with skin and soft-tissue infections annually in the United States. Given the importance of these types of infections, more robust and reliable estimates are needed to better quantitate the occurrence and understand the impact of interventions. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Maribeth C Lovegrove; Deborah Dowell; Andrew I Geller; Sandra K Goring; Kathleen O Rose; Nina J Weidle; Daniel S Budnitz Journal: Am J Public Health Date: 2019-03-21 Impact factor: 9.308
Authors: Sarah E Rudasill; Yas Sanaiha; Alexandra L Mardock; Habib Khoury; Hanning Xing; James W Antonios; James A McKinnell; Peyman Benharash Journal: J Am Coll Cardiol Date: 2019-02-12 Impact factor: 24.094
Authors: Salil V Deo; Sajjad Raza; Ankur Kalra; Vaishali S Deo; Salah E Altarabsheh; Aisha Zia; Muhammad Shahzeb Khan; Alan H Markowitz; Joseph F Sabik; Soon J Park Journal: J Am Coll Cardiol Date: 2018-04-10 Impact factor: 24.094
Authors: Chanu Rhee; Raymund Dantes; Lauren Epstein; David J Murphy; Christopher W Seymour; Theodore J Iwashyna; Sameer S Kadri; Derek C Angus; Robert L Danner; Anthony E Fiore; John A Jernigan; Greg S Martin; Edward Septimus; David K Warren; Anita Karcz; Christina Chan; John T Menchaca; Rui Wang; Susan Gruber; Michael Klompas Journal: JAMA Date: 2017-10-03 Impact factor: 56.272
Authors: Andrew D Wiese; Marie R Griffin; C Michael Stein; William Schaffner; Robert A Greevy; Edward F Mitchel; Carlos G Grijalva Journal: BMJ Open Date: 2018-06-19 Impact factor: 2.692
Authors: Robert W Pinner; Ruth Lynfield; James L Hadler; William Schaffner; Monica M Farley; Mark E Frank; Anne Schuchat Journal: Emerg Infect Dis Date: 2015-09 Impact factor: 6.883
Authors: David Goodman-Meza; Amber Tang; Babak Aryanfar; Sergio Vazquez; Adam J Gordon; Michihiko Goto; Matthew Bidwell Goetz; Steven Shoptaw; Alex A T Bui Journal: Open Forum Infect Dis Date: 2022-09-12 Impact factor: 4.423
Authors: Laura R Marks; Juan J Calix; John A Wildenthal; Meghan A Wallace; Sanjam S Sawhney; Eric M Ransom; Michael J Durkin; Jeffrey P Henderson; Carey-Ann D Burnham; Gautam Dantas Journal: Commun Med (Lond) Date: 2021-11-30
Authors: Khawaja M Talha; Mark J Dayer; Martin H Thornhill; Wajeeha Tariq; Verda Arshad; Imad M Tleyjeh; Kent R Bailey; Raj Palraj; Nandan S Anavekar; M Rizwan Sohail; Daniel C DeSimone; Larry M Baddour Journal: Open Forum Infect Dis Date: 2021-09-25 Impact factor: 4.423
Authors: Gregg S Gonsalves; A David Paltiel; Thomas Thornhill; Suzan Iloglu; Alfred DeMaria; Kevin Cranston; R Monina Klevens; Rochelle P Walensky; Joshua L Warren Journal: Open Forum Infect Dis Date: 2021-03-15 Impact factor: 4.423
Authors: Mary C Figgatt; Zach R Salazar; Louise Vincent; Diannee Carden-Glenn; Kelly Link; Lauren Kestner; Tyler Yates; Asher Schranz; Elizabeth Joniak-Grant; Nabarun Dasgupta Journal: Harm Reduct J Date: 2021-07-30